ALVEOLIX AG

AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at improving preclinical decision-making and thus reducing drug development costs. AlveoliX aims at changing the way drug development research is done today by providing in-vitro models that reproduce the in-vivo environment in an unprecedented way. These in-vitro models, called organ-on-chips, will make it possible to better predict drugs’ responses in humans than standard in-vitro and in-vivo models and as a consequence to importantly reduce animal testing.